AZTA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

146.89M

-0.42%

0.132

+64.59%

148.93M

+3.84%

0.157

+213.34%

155.09M

+7.75%

0.217

+14.04%

Estimates Revision

The market is revising Downward the revenue expectations for Azenta, Inc. (AZTA) for FY2026, with the revenue forecasts being adjusted by -0.1% over the past three months. During the same period, the stock price has changed by 16.35%.

Revenue Estimates for FY2026

Revise Downward

-0.1%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+0.52%

In Past 3 Month

Stock Price

Go Up

+16.35%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast AZTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZTA is 37.33 USD with a low forecast of 31.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

31.00

Averages

37.33

High

45.00

Current: 0.000

Low

31.00

Averages

37.33

High

45.00

Evercore ISI

In Line -> Outperform

upgrade

$34 -> $50

2026-01-05

New

Reason

Evercore ISI

Price Target

$34 -> $50

2026-01-05

New

upgrade

In Line -> Outperform

Reason

Evercore ISI upgraded Azenta to Outperform from In Line with a price target of $50, up from $34.

Needham

Buy

maintain

$42 -> $44

2025-12-19

Reason

Needham

Price Target

$42 -> $44

2025-12-19

maintain

Buy

Reason

Needham raised the firm's price target on Azenta to $44 from $42 and keeps a Buy rating on the shares. The firm cites the company's management providing a long range plan that included FY28 financial targets and maintains that its continued margin improvement should result in strong earnings growth over the next few years, the analyst tells investors in a research note.

Raymond James

Andrew Cooper

Outperform

maintain

$35 -> $45

2025-11-25

Reason

Raymond James

Andrew Cooper

Price Target

$35 -> $45

2025-11-25

maintain

Outperform

Reason

Raymond James analyst Andrew Cooper raised the firm's price target on Azenta to $45 from $35 and keeps an Outperform rating on the shares following a fiscal Q4 report that the firm describes as "generally in line to above hopes." An investor day in just a few weeks should "shed major light on the longer-term view," says the analyst, who thinks it will be in the mid-single-digit-plus organic revenue range with a path to margins breaching 20%, leaving the firm "optimistic on the trajectory."

Nephron Research

Thomas DeBourcy

Sell -> Hold

upgrade

$31

2025-11-24

Reason

Nephron Research

Thomas DeBourcy

Price Target

$31

2025-11-24

upgrade

Sell -> Hold

Reason

Nephron Research analyst Thomas DeBourcy upgraded Azenta to Hold from Sell with a $31 price target.

Jefferies

Hold

Buy

upgrade

$30 -> $38

2025-10-30

Reason

Jefferies

Price Target

$30 -> $38

2025-10-30

upgrade

Hold

Buy

Reason

Jefferies upgraded Azenta to Buy from Hold with a price target of $38, up from $30. The firm sees an attractive setup for the shares into 2026. The company has "healthy" biopharma exposure and "plenty of growth drivers" from innovation, pricing, attach rates and potential acquisitions, the analyst tells investors in a research note. Jefferies believes the shares can re-rate higher as investors gain confidence in Azenta's mid-term opportunity.

Raymond James

Market Perform

Outperform

upgrade

$35

2025-08-06

Reason

Raymond James

Price Target

$35

2025-08-06

upgrade

Market Perform

Outperform

Reason

Raymond James upgraded Azenta to Outperform from Market Perform with a $35 price target. While the Q3 print was \"noisy,\" it drove the stock to a level that the firm believes will be a bottom, the analyst tells investors in a research note. Raymond James views the Q3 results as a clearing event and is hopeful that \"reasonable\" performance going forward, especially if/when the end market improves, supports a return to more reasonable multiples.

Valuation Metrics

The current forward P/E ratio for Azenta Inc (AZTA.O) is 42.36, compared to its 5-year average forward P/E of 189.87. For a more detailed relative valuation and DCF analysis to assess Azenta Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

189.87

Current PE

42.36

Overvalued PE

490.57

Undervalued PE

-110.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

35.90

Current EV/EBITDA

12.19

Overvalued EV/EBITDA

62.34

Undervalued EV/EBITDA

9.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.49

Current PS

2.48

Overvalued PS

8.54

Undervalued PS

2.44

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AZTA News & Events

Events Timeline

No data

News

4.0

2025-12-31NASDAQ.COM

AZENTA Inc. (AZTA) Rating Upgraded to 80% Reflecting Strong Fundamentals

7.5

2025-12-29NASDAQ.COM

Azenta (AZTA) Sells B Medical Systems for $63 Million to THELEMA S.À R.L.

8.5

2025-12-29PRnewswire

Azenta Sells B Medical Systems for $63 Million to THELEMA S.À R.L.

People Also Watch

Frequently Asked Questions

What is Azenta Inc (AZTA) stock price today?

The current price of AZTA is 37.5 USD — it has decreased -0.03 % in the last trading day.

What is Azenta Inc (AZTA)'s business?

Azenta, Inc. is a provider of life sciences solutions worldwide. The Company provides a full suite of cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions globally. The Company's segments include Sample Management Solutions and Multiomics. Its Sample Management Solutions segment offers end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Company's Multiomics segment includes its genomic services business, which advances research and development activities by providing gene sequencing, synthesis, editing and related services. The Company's brands include GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

What is the price predicton of AZTA Stock?

What is Azenta Inc (AZTA)'s revenue for the last quarter?

Azenta Inc revenue for the last quarter amounts to 158.95M USD, increased 5.21 % YoY.

What is Azenta Inc (AZTA)'s earnings per share (EPS) for the last quarter?

Azenta Inc. EPS for the last quarter amounts to 1.11 USD, decreased -1025.00 % YoY.

What changes have occurred in the market's expectations for Azenta Inc (AZTA)'s fundamentals?

How many employees does Azenta Inc (AZTA). have?

Azenta Inc (AZTA) has 3000 emplpoyees as of January 09 2026.

What is Azenta Inc (AZTA) market cap?

Today AZTA has the market capitalization of 1.72B USD.